Colossal Biosciences expanded its Series C funding with an additional $120 million, bringing total funds raised to over $555 million. The Dallas-based firm is expanding its avian genetics group focused on de-extinction projects like reviving the dodo and woolly mammoth. The company’s advancements include growing and gene editing pigeon primordial germ cells intended as surrogates for extinct and endangered birds. The launch of the Mauritius Dodo Advisory Committee highlights commitment to responsible rewilding. These developments underscore growing investment in genetic conservation and de-extinction technologies.